Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00961454 · ClinicalTrials.gov registry record · Phase 1
Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00961454: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00961454 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00961454, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
A pilot study to evaluate the ability of photobiomodulation to alter cerebral blood flow in the frontal poles and to affect the emotional status of patients with major depression.
Interventions
- DEVICE Photobiomodulation with a super-luminous light emitting diode
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00961454
The ClinicalTrials.gov registry entry for NCT00961454 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Photobiomodulation with a super-luminous light emitting diode is the first listed.
NCT00961454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00961454 about?
NCT00961454 is a clinical study titled "Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression". A pilot study to evaluate the ability of photobiomodulation to alter cerebral blood flow in the frontal poles and to affect the emotional status of patients with major depression.
What is the current status of trial NCT00961454?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00961454?
The interventions under investigation include: Photobiomodulation with a super-luminous light emitting diode (DEVICE).
Who is sponsoring clinical trial NCT00961454?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.